 | | Vol. 11.43 – 20 November, 2020 |
| |
|
|
| Target analysis of hit compounds revealed androgen signaling as a key modulator of angiotensin converting enzyme 2 (ACE2) levels. Treatment with antiandrogenic drugs reduced ACE2 expression and protected human embryonic stem cell-derived lung organoids against SARS-CoV-2 infection.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4+FOXP3– T-cells were increased compared to CDK12-proficient controls.
[Clinical Cancer Research] |
|
|
|
| Scientists investigated the scope of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression in end-stage prostate cancer, the basis for CEACAM5 enrichment in euroendocrine prostate cancer, and the therapeutic potential of the CEACAM5 antibody-drug conjugate labetuzumab govitecan in prostate cancer.
[Clinical Cancer Research] |
|
|
|
| The expression of MYC was positively associated with that of key fatty acid synthesis genes including ACLY, ACC1, and FASN in prostate cancer TCGA dataset. Chromatin immunoprecipitation revealed Myc occupancy at the promoters of ACLY, ACC1, and FASN.
[Oncogene] |
|
|
|
| Investigators demonstrated that high levels of plectin are associated with localized and metastatic human prostate cancer when compared to benign prostate tissues.
[Oncogene] |
|
|
|
| Scientists showed that Hoxb9 could promote adrenal tumor progression in a sex-dependent manner and identified HOX factors as potential drug targets, leading to novel therapeutic approaches in adrenocortical carcinoma.
[British Journal of Cancer] |
|
|
|
| Researchers investigated the antiproliferative activity of mycelium extracts and F. officinalis sporocarps against the the DU145 prostate cancer cell line, a melanoma cell line and a lung cancer cell line.
[Scientific Reports] |
|
|
|
|
| The authors discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.
[Nature Cancer] |
|
|
|
| Curcumin, a turmeric-derived polyphenol, has been reported to possess antiproliferative and proapoptotic properties. Scientists summarize all the in vitro and in vivo studies examining the effects of curcumin in prostate cancer.
[Biomolecules] |
|
|
|
|
| Clinical Laserthermia Systems AB (CLS) announced the clinical study performed in collaboration with Toronto General Hospital and Dr. Sangeet Ghai is now recruiting patients for the extended Phase II trial where 30 additional patients, with localized low or intermediate risk prostate cancer, will be treated with MRI-guided focal laser ablation.
[Clinical Laserthermia Systems AB (GlobeNewswire, Inc.)] |
|
|
|
|
| May 16 – May 21, 2021
Lucca, Italy |
|
|
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | The University of British Columbia (UBC) – Vancouver, British Columbia, Canada |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
